AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-2 (canceled).

3 (previously presented). 2-((2-Bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate.

4 (currently amended). A nitroaniline-based unsymmetrical mustard represented by formula (IIIb)



(IIIb)

wherein

X represents one of the groups NO_2, CN, or SO_2R^1, where R^1 represents a C_{1-6}-alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

Y represents one of the groups OR^2, $NHCOR^2$, $CONHR^2CO_2R^3$,

$CONHR^2$morpholide, $CONHR^2$ other than $CONH_2$, $CONR^2R^3$ other than $CONH_2$, $CONHOR^2$, $CONHSO_2R^2$, SO_2NH_2, SO_2NHR^2 or $SO_2NR^2R^3$ wherein each R^2 and R^3 independently represent a H, C_{1-6}- alkyl or C_{1-6}-alkylene optionally substituted with one or more hydroxy and/or one or more amino groups; and A and B each independently represent halogen, OSO_2R^4, OSO_2NH_2, OSO_2NHR^4 or $OSO_2NR^4R^5$, wherein each R^4 and R^5 independently represent a C_{1-6}- alkyl optionally substituted with one or more hydroxy and/or one or more amino groups; and pharmaceutically acceptable derivatives and salts thereof.

5-7 (canceled).

8 (currently amended). A method of preparing a nitroaniline-based unsymmetrical mustard represented by formula (IIIb) as claimed in claim 4



(IIIb)

wherein

X represents one of the groups NO_2, CN, or SO_2R^1, where R^1 represents a C_{1-6}-

alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

Y represents one of the groups OR^2, $NHCOR^2$, $CONHR^2CO_2R^3$, $CONHR^2$morpholide, $CONHR^2$ other than $CONH_2$, $CONR^2R^3$ other than $CONH_2$, $CONHOR^2$, $CONHSO_2R^2$, SO_2NH_2, SO_2NHR^2 or $SO_2NR^2R^3$ wherein each R^2 and R^3 independently represent a H, C_{1-6}- alkyl or C_{1-6}-alkylene optionally substituted with one or more hydroxy and/or one or more amino groups; and A and B each independently represent halogen, OSO_2R^4, OSO_2NH_2, OSO_2NHR^4 or $OSO_2NR^4R^5$, wherein each R^4 and R^5 independently represent a C_{1-6}- alkyl optionally substituted with one or more hydroxy and/or one or more amino groups; and pharmaceutically acceptable derivatives and salts thereof;

the method comprising the step of reacting a compound of formula



with an amount of LiBr in a polar solvent to give a bromo mesylate of formula (IIIb).

9 (previously presented). The method as claimed in claim 8 wherein the polar solvent is selected from the group consisting of acetonitrile, dimethylformamide, ethyl acetate, triethylamine, acetone and mixtures thereof.

10 (previously presented). The method as claimed in claim 8 wherein the alkali metal halide is selected from the group consisting of LiCl, LiBr, NaI and NaBr.

11 (previously presented). A compound of formula (IIIb) obtained by any one of the methods as claimed in claim 8.

12-15 (canceled).

16 (previously presented). A method of cell ablation therapy utilising at least one endogenous nitroreductase enzyme, the method comprising the step of administering a compound of Formula (IIIb) as claimed in claim 4 in a "therapeutically effective amount" to ablate tumour cells in tissue in a subject, wherein said tissue expresses at least one endogenous nitroreductase enzyme, to activate the compound of formula (IIIb) into an active metabolite to ablate the tumor cells.

17-18 (canceled).

19 (previously presented). A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (IIIb) as defined in claim 4 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.

20-21(canceled).

22 (new). A nitroaniline-based unsymmetrical mustard as claimed in claim 4, wherein Y is $CONHR_2$ where R_2 is C_1-C_6 alkylene substituted with hydroxyl.

23(new). A nitroaniline-based unsymmetrical mustard as claimed in claim 4, wherein Y is $CONHCH_2CH_2OH$.